Scholarlink

<p>Ferroptosis represents one of important no-apoptotic programmed cell death with over accumulation of iron- and reactive oxygen species (ROS). While its key role and trials for cancer therapy, achieving precise and potent induction ferroptosis in cancer cells with massive amplification of cellular lipid peroxidation and iron overloading, remains a significant hurdle. Herein, we developed a biomimetic red blood cell membranes (RBCM) camouflaged β-lapachone (Lap) and hemin nanoassembly (LHNPs@RBCM) as ferroptosis inducer for hepatocellular carcinoma (HCC) therapy. The RBCM endowed the nanoassembly with prolonged systemic circulation and improved tumor accumulation. After endocytosis of LHNPs@RBCM by cancer cells, the cancer-specific overexpressed NAD(P)H: quinone oxidoreductase (NQO1) converted the released Lap to ROS (e.g. O<sub>2</sub>.<sup>−</sup>, H<sub>2</sub>O<sub>2</sub>) with good selectivity, while hemin reacted with H<sub>2</sub>O<sub>2</sub> and turned the less reactive H<sub>2</sub>O<sub>2</sub> into highly reactive hydroxyl radical (·OH) by Fenton reaction. These ·OH reacted with polyunsaturated fatty acids (PUFAs), triggering lethal lipid peroxides (LPO) and subsequent ferroptosis. Additionally, the ROS induced activation of the NRF2 pathway, which in turn upregulates NQO1 and heme oxygenase 1 (HO-1), creating a positive feedback loop that further elevates H<sub>2</sub>O<sub>2</sub> levels and labile iron pools. Due to the combination of classical GPX4 suppression pathway by ROS with a non-classical HO-1-mediated iron overload mechanism for ferroptosis, the LHNPs@RBCM effectively killed cancer cells in both cellular and animal models. The excellent therapeutic effect of LHNPs@RBCM demonstrated it as a transformative strategy for clinical ferroptosis-based therapy.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biomimetic β-lapachone and hemin nanoassembly for intracellular oxidation cascade amplified ferroptosis in hepatocellular carcinoma therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月28日

查看全文
  • Jiyue Wang,
  • Yongyi Liang,
  • Wenxiang Qi,
  • Wenjun Li,
  • Donglin He,
  • Lei Ding,
  • Lingjie Wu,
  • Ming Wu,
  • Yupeng Sun,
  • Yongyi Zeng,
  • Xiaolong Liu,
  • Yao Huang,
  • Jingfeng Liu,
  • Xiaolong Zhang

摘要

Ferroptosis represents one of important no-apoptotic programmed cell death with over accumulation of iron- and reactive oxygen species (ROS). While its key role and trials for cancer therapy, achieving precise and potent induction ferroptosis in cancer cells with massive amplification of cellular lipid peroxidation and iron overloading, remains a significant hurdle. Herein, we developed a biomimetic red blood cell membranes (RBCM) camouflaged β-lapachone (Lap) and hemin nanoassembly (LHNPs@RBCM) as ferroptosis inducer for hepatocellular carcinoma (HCC) therapy. The RBCM endowed the nanoassembly with prolonged systemic circulation and improved tumor accumulation. After endocytosis of LHNPs@RBCM by cancer cells, the cancer-specific overexpressed NAD(P)H: quinone oxidoreductase (NQO1) converted the released Lap to ROS (e.g. O2.−, H2O2) with good selectivity, while hemin reacted with H2O2 and turned the less reactive H2O2 into highly reactive hydroxyl radical (·OH) by Fenton reaction. These ·OH reacted with polyunsaturated fatty acids (PUFAs), triggering lethal lipid peroxides (LPO) and subsequent ferroptosis. Additionally, the ROS induced activation of the NRF2 pathway, which in turn upregulates NQO1 and heme oxygenase 1 (HO-1), creating a positive feedback loop that further elevates H2O2 levels and labile iron pools. Due to the combination of classical GPX4 suppression pathway by ROS with a non-classical HO-1-mediated iron overload mechanism for ferroptosis, the LHNPs@RBCM effectively killed cancer cells in both cellular and animal models. The excellent therapeutic effect of LHNPs@RBCM demonstrated it as a transformative strategy for clinical ferroptosis-based therapy.

Graphical Abstract